fleroxacin has been researched along with pefloxacin in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (38.71) | 18.7374 |
| 1990's | 12 (38.71) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 2 (6.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MA; Domagala, JM; Mailloux, GB; Roland, GE; Suto, MJ | 1 |
| Domagala, JM; Hanna, LD; Heifetz, CL; Hutt, MP; Mich, TF; Sanchez, JP; Solomon, M | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Amyes, SG; Lewin, CS | 1 |
| Anderson, R; Joone, G; van Rensburg, CE | 1 |
| Christ, W | 1 |
| Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H | 1 |
| Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B | 1 |
| Deforges, L; Duval, J; Leclercq, R; Soussy, CJ | 1 |
| Barzilai, A; Keren, G; Leibovitz, E; Rubinstein, E; Shabtai, M | 1 |
| Aubert, G; Denis, M; Dorche, G; Loboguerrero, M; Lucht, F; Puech, C | 1 |
| Akalin, HE; Akyön, Y; Diker, S; Gür, D; Hasçelik, G | 1 |
| Fass, RJ; Helsel, VL | 1 |
| Clarke, AM; Zemcov, SJ | 1 |
| Habiyaremye, I; Vandepitte, J; Verbist, L | 1 |
| Claeys, G; Van den Abeele, AM; Verschraegen, G | 1 |
| De Lepeleire, I; De Schepper, PJ; Tjandra-Maga, TB; Van Hecken, A; Verbesselt, R | 1 |
| Bremner, DA; Dickie, AS; Singh, KP | 1 |
| Fernandes, PB; Swanson, RN | 1 |
| Arman, D; Tural, D; Willke, A | 1 |
| Goldwasser, R; Keren, G; Keysary, A; Rubinstein, E | 1 |
| Griffiths, NM; Hirst, BH; Simmons, NL | 1 |
| Kinzig, M; Naber, KG; Savov, O; Sörgel, F; Theuretzbacher, U | 1 |
| Baumann-Wilschke, I; Förster, C; Rücker, M; Shakibaei, M; Stahlmann, R; Vormann, J | 1 |
| Ooie, T; Sugiyama, Y; Suzuki, H; Terasaki, T | 1 |
| Bouquet, S; Couet, W; de Boer, AG; de Lange, EC; Delon, A; Marchand, S; van den Berg, D; van der Sandt, IC | 1 |
1 review(s) available for fleroxacin and pefloxacin
| Article | Year |
|---|---|
Pharmacokinetics of quinolones in renal insufficiency.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Glomerular Filtration Rate; Half-Life; Humans; Kidney Failure, Chronic; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones | 1990 |
2 trial(s) available for fleroxacin and pefloxacin
| Article | Year |
|---|---|
Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
Topics: Administration, Oral; Adult; Ciprofloxacin; Fleroxacin; Humans; Male; Pefloxacin; Random Allocation | 1988 |
Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Cross-Over Studies; Enterobacteriaceae; Escherichia coli; Female; Fleroxacin; Humans; Male; Microbial Sensitivity Tests; Pefloxacin; Pseudomonas; Streptococcus; Urinary Tract Infections | 1998 |
28 other study(ies) available for fleroxacin and pefloxacin
| Article | Year |
|---|---|
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.
Topics: Animals; Anti-Infective Agents; Cricetinae; Cricetulus; Fluoroquinolones; Microbial Sensitivity Tests; Structure-Activity Relationship | 1992 |
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
Topics: Anti-Bacterial Agents; Bacteria; DNA, Bacterial; DNA, Superhelical; Escherichia coli; Microbial Sensitivity Tests; Naphthyridines; Plasmids; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1986 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
Topics: Anti-Infective Agents; Bacterial Proteins; Chloramphenicol; Ciprofloxacin; Escherichia coli; Fleroxacin; Pefloxacin; Rifampin; RNA, Bacterial | 1990 |
Interactions of the oxygen-dependent antimicrobial system of the human neutrophil with difloxacin, ciprofloxacin, pefloxacin and fleroxacin in the intraphagocytic eradication of Staphylococcus aureus.
Topics: Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Granulomatous Disease, Chronic; Humans; Neutrophils; Pefloxacin; Phagocytosis; Staphylococcus aureus | 1990 |
Central nervous system toxicity of quinolones: human and animal findings.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Central Nervous System; Ciprofloxacin; Dogs; Drug Interactions; Fleroxacin; Fluoroquinolones; gamma-Aminobutyric Acid; Humans; Injections, Intraventricular; Narcotic Antagonists; Pefloxacin; Quinolizines; Seizures; Theophylline | 1990 |
Quinolone pharmacokinetics and metabolism.
Topics: Administration, Oral; Anti-Infective Agents; Biological Availability; Biotransformation; Ciprofloxacin; Enoxacin; Fleroxacin; Half-Life; Humans; Metabolic Clearance Rate; Norfloxacin; Ofloxacin; Pefloxacin | 1990 |
[In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fleroxacin; Microbial Sensitivity Tests; Nalidixic Acid; Pefloxacin | 1989 |
The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.
Topics: Abscess; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Enterobacteriaceae Infections; Female; Fleroxacin; Half-Life; Pefloxacin; Rats; Serratia marcescens | 1989 |
[Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enoxacin; Escherichia coli; Fleroxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Pefloxacin; Pseudomonas aeruginosa; Serratia marcescens | 1989 |
[In vitro susceptibility of Campylobacter jejuni and Campylobacter coli to quinolone antibiotics].
Topics: Anti-Infective Agents; Campylobacter; Campylobacter jejuni; Ciprofloxacin; Feces; Fleroxacin; Humans; Microbial Sensitivity Tests; Ofloxacin; Pefloxacin | 1989 |
In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Fleroxacin; Humans; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1987 |
In vitro activity of the new 4-quinolone compound Ro 23-6240.
Topics: Anti-Bacterial Agents; Bacteria; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Microbial; Enterobacteriaceae; Fleroxacin; Gentamicins; Haemophilus influenzae; Microbial Sensitivity Tests; Nalidixic Acid; Norfloxacin; Pefloxacin; Pseudomonas aeruginosa; Staphylococcus aureus | 1987 |
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Topics: Anti-Bacterial Agents; Campylobacter fetus; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1987 |
Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
Topics: Amikacin; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Cefaclor; Ceftazidime; Cefuroxime; Ciprofloxacin; Clavulanic Acids; Corynebacterium; Drug Combinations; Drug Resistance, Microbial; Fleroxacin; Norfloxacin; Pefloxacin; Piperacillin; Staphylococcus; Vancomycin | 1988 |
In-vitro activity of fleroxacin compared with three other quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin | 1988 |
Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones | 1988 |
In vitro activity of eight antibiotics against Salmonella and Shigella species.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fleroxacin; Microbial Sensitivity Tests; Ofloxacin; Pefloxacin; Salmonella; Shigella; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
The inhibitory effect of fluoroquinolones on Coxiella burnetii growth in in-vitro systems.
Topics: Animals; Anti-Infective Agents; Chick Embryo; Chlorocebus aethiops; Ciprofloxacin; Coxiella burnetii; Fleroxacin; Microbial Sensitivity Tests; Minocycline; Pefloxacin; Vero Cells | 1994 |
Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway?
Topics: Biological Transport; Carbon Radioisotopes; Cells, Cultured; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Humans; Intestinal Mucosa; Norfloxacin; Ofloxacin; Pefloxacin; Quinolizines | 1994 |
Effects of fluoroquinolones and magnesium deficiency in murine limb bud cultures.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryonic and Fetal Development; Extremities; Fleroxacin; Fluoroquinolones; Magnesium Deficiency; Mice; Microscopy, Electron; Ofloxacin; Pefloxacin; Quinolones | 1998 |
Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Biological Transport; Choroid Plexus; Fleroxacin; Fluoroquinolones; Injections, Intraventricular; Male; Pefloxacin; Probenecid; Quinolones; Rats; Rats, Wistar | 1996 |
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Cell Line; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Infusions, Intra-Arterial; Kidney; Mice; Mice, Inbred Strains; Mice, Knockout; Microdialysis; Norfloxacin; Pefloxacin; Recombinant Proteins; Rhodamine 123; Swine; Tissue Distribution; Transfection | 2000 |